Gilead Sciences Completes Acquisition of CV Therapeutics
17 Abril 2009 - 3:15PM
Business Wire
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that it has
completed its acquisition of CV Therapeutics, Inc. (Nasdaq:
CVTX).
On April 17, 2009, CV Therapeutics merged with a wholly-owned
subsidiary of Gilead. As a result of the merger, each outstanding
share of CV Therapeutics not owned by Gilead, its subsidiaries or
CV Therapeutics has been automatically converted into the right to
receive $20.00 in cash, without interest, subject to appraisal
rights. CV Therapeutics stockholders who did not tender their
shares will receive a Notice of Merger and a Letter of Transmittal
that will instruct them as to how to receive the merger
consideration. The merger follows a cash tender offer for all
outstanding shares of CV Therapeutics common stock at $20.00 per
share, which was completed at one minute following 11:59 p.m., New
York City time (midnight), on April 14, 2009.
About Gilead
Sciences
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of
unmet medical need. The company�s mission is to advance the care of
patients suffering from life-threatening diseases worldwide.
Headquartered in Foster City, California, Gilead has operations in
North America, Europe and Australia.
Forward Looking
Statements
This press release includes forward-looking statements, within
the meaning of the Private Securities Litigation Reform Act of
1995, that are subject to risks, uncertainties and other factors
including the risks and uncertainties related to Gilead�s ability
to successfully integrate the products and employees of Gilead and
CV Therapeutics, its ability to increase sales of CV Therapeutics�
approved products and its ability to advance pipeline programs.
These risks, uncertainties and other factors, and the general risks
associated with Gilead�s business as described in reports and other
documents filed with the Securities and Exchange Commission, could
cause actual results to differ materially from those referred to in
the forward-looking statements. The reader is cautioned not to rely
on these forward-looking statements. All forward-looking statements
are based on information currently available to Gilead and Gilead
assumes no obligation to update any such forward-looking statements
or other statements included in this press release.
For more information on Gilead,
please call the Gilead Public Affairs Department at 1-800-GILEAD-5
(1-800-445-3235) or visit www.gilead.com.
CV Therapeutics (NASDAQ:CVTX)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
CV Therapeutics (NASDAQ:CVTX)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024
Real-Time news about CV Therapeutics (MM) (NASDAQ): 0 recent articles
Más de Artículos de Noticias